Clinical Trials Logo

NSCLC Harboring NRG1 Fusion clinical trials

View clinical trials related to NSCLC Harboring NRG1 Fusion.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05588609 Recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Start date: November 17, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC

NCT ID: NCT02912949 Recruiting - NRG1 Fusion Clinical Trials

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Start date: January 2015
Phase: Phase 2
Study type: Interventional

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)